Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

recombinant human EGF-rP64K/Montanide ISA 51 vaccine

A peptide vaccine preparation, containing recombinant human epidermal growth factor (rEGF) linked to the Neisseria meningitidis-derived recombinant immunogenic carrier protein P64k (rP64k) and mixed with the immunoadjuvant Montanide ISA 51, with potential active immunotherapy activity. Recombinant human EGF-rP64K/Montanide ISA 51 vaccine may trigger a humoral immune response against vaccine rEGF and rP64K and, so, against endogenous EGF. Antibody-mediated inhibition of endogenous EGF binding to its receptor, epithelial growth factor receptor (EGFR), may result in the inhibition of tumor cell proliferation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Center of Molecular Immunology (CIMA) epidermal growth factor (EGF) vaccine
Center of Molecular Immunology epidermal growth factor vaccine
CIMAvax EGF
CIMAvax epidermal growth factor vaccine
CimaVax vaccine
CIMAvax-EGF
recombinant human EGF-P64K/Montanide vaccine
Abbreviation:Cimavax
CimaVax
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search